ArticleCells2025
Multipotent Mesenchymal Stem Cell Therapy for Vascular Dementia.
Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Cerebrovascular Injury to Vascular Cognitive Impairment and Dementia: Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles.Biomedicines · 2026Review
- The protection of mesenchymal stem cells in metabolic reprogramming and endothelial-mesenchymal transition in diabetic aortas.Stem cells translational medicine · 2026Article
- Tanshinone IIA attenuates cognitive impairment in vascular dementia rats by modulating copper homeostasis via the SLC31A1/FDX1 axis.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular dementia (VD), characterized by cognitive decline and behavioral disorders, has seen a rapid increase in prevalence in recent years. However, effective treatments for VD remain unavailable. Due to its regenerative potential, stem cell therapy has garnered attention as a promising approach for VD treatment, yet it has shown limited effects on cognitive and behavioral impairments caused by the disease. To address this limitation, this study aimed to develop a novel treatment using human embryonic stem cell-derived multipotent mesenchymal stem cells (MMSCs). The therapeutic efficacy of MMSCs was evaluated using a vascular dementia mouse model induced by bilateral carotid artery stenosis (BCAS). The effects of MMSCs were assessed through behavioral tests and postmortem brain tissue analysis, including mRNA expression analysis and hematoxylin and eosin (H&E) staining. MMSCs treatment significantly improved both working memory and long-term memory. Histological analysis revealed enhanced angiogenesis, preservation of blood-brain barrier integrity, and improved hippocampal organization. Furthermore, MMSCs treatment reduced the expression of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.